Arriving in the landscape of weight management therapy, retatrutide is a distinct strategy. Unlike many existing medications, retatrutide operates as a twin agonist, at once affecting both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) binding sites. The dual engagement fosters various advantageous effects, like improved